Regencell Bioscience Holdings SG&A Expenses 2020-2024 | RGC

Regencell Bioscience Holdings sg&a expenses for the twelve months ending June 30, 2024 were $0M, a 0% increase year-over-year.

  • Regencell Bioscience Holdings annual sg&a expenses for 2024 were $0.004B, a 21.76% decline from 2023.
  • Regencell Bioscience Holdings annual sg&a expenses for 2023 were $0.005B, a 8.11% decline from 2022.
  • Regencell Bioscience Holdings annual sg&a expenses for 2022 were $0.005B, a 441.46% increase from 2021.

Regencell Bioscience Holdings SG&A Expenses 2020-2024 | RGC

  • Regencell Bioscience Holdings annual sg&a expenses for 2024 were $0.004B, a 21.76% decline from 2023.
  • Regencell Bioscience Holdings annual sg&a expenses for 2023 were $0.005B, a 8.11% decline from 2022.
  • Regencell Bioscience Holdings annual sg&a expenses for 2022 were $0.005B, a 441.46% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$222.8B
Amgen (AMGN)$162B
Gilead Sciences (GILD)$140.6B
Vertex Pharmaceuticals (VRTX)$118.3B
Bristol Myers Squibb (BMY)$96.7B
CSL (CSLLY)$85.2B
GSK (GSK)$76.5B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$42.3B
Argenex SE (ARGX)$36.4B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.8B
Insmed (INSM)$19.3B
Biogen (BIIB)$18.9B
Illumina (ILMN)$17.4B
Genmab (GNMSF)$15.2B
Genmab (GMAB)$14.8B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.1B
Exelixis (EXEL)$12.1B
QIAGEN (QGEN)$11.3B
BioMarin Pharmaceutical (BMRN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Legend Biotech (LEGN)$7.6B